Bioquell Regulatory News (BQE)

19 May 2008 07:00



TO: CITY EDITORS 

FOR IMMEDIATE RELEASE

19 May, 2008

BIOQUELL PLC

Interim Management Statement

(BIOQUELL PLC is publishing this announcement pursuant to the UK Listing Authority's Disclosure and Transparency Rules which revised and added to the requirements on periodic financial reporting for UK listed companies, including the requirement for Interim Management Statements to be issued twice a year.)

BIOQUELL PLC ("BIOQUELL") (LSE symbol: BQE), the UK leader in specialist decontamination technology and testing/compliance services, announces its Interim Management Statement for the period from 1 January, 2008 to 19 May, 2008.

Financial position and performance of the Company

Group revenues in the first four months of the year were in line with the Board's forecasts and above the same period last year.

The Group has seen increased interest, in the UK and internationally, in the use of its hydrogen peroxide vapour ("HPV") decontamination technology to combat hospital acquired infection / "superbugs" contaminating healthcare equipment and facilities. BIOQUELL is considering a number of ways to accelerate the international roll out of its unique HPV technology in the healthcare sector. Good progress has also been made on collaborative academic research demonstrating further the key role of the hospital environment in the spread of certain "superbugs".

HPV equipment sales to the life sciences sector have shown strong growth in the period.

The Group continues to make good progress in expanding its activities and product range in the defence sector, particularly in the United States.

Trading in the TRAC division has been broadly flat - with some businesses showing robust growth and others showing a reduction, although a significant element of this reduction relates to disruption from a facility move which started at the end of 2007 and carried on into the first quarter of 2008.

The Group's balance sheet remains strong - with the net cash position increasing significantly since the year end.

Enquiries

John Salkeld BIOQUELL PLC 01264 835 900

Nick Adams

Mark Bodeker